Do I need a prescription for Ergocalciferol 400,000units/2ml solution for injection ampoules?

Ergocalciferol 400,000units/2ml solution for injection ampoules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Ergocalciferol 400,000units/2ml solution for injection ampoules?

Ergocalciferol 400,000units/2ml solution for injection ampoules is the generic name. It is available under brand names including: Ergocalciferol 400,000units/2ml solution for injection ampoules. (Source: NHS dm+d — Actual Medicinal Products)

Ergocalciferol 400,000units/2ml solution for injection ampoules

Prescription only

Requires a prescription from a doctor or prescriber

Injection

000units/2ml

Parenteral

Oral liquids

Vitamins

Active ingredients:

Ergocalciferol

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 09.06.04

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC A11CC01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Ergocalciferol

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Ergocalciferol

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Browse all Drug Analysis Profiles A–Z

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Ergocalciferol

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Ergocalciferol on the MHRA register

Ergocalciferol 400,000units/2ml solution for injection ampoules

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Calcifediol 266microgram capsules

Capsule

Same therapeutic group

Colecalciferol 3,000units/dose oral spray sugar free

Spray

000units

Same therapeutic group

Colecalciferol 4,000units/dose oral spray sugar free

Spray

000units

Same therapeutic group

Colecalciferol 400units/drop oral drops sugar free

Other

400units

Same therapeutic group

Colecalciferol 1,000units/drop oral drops sugar free

Other

000units

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Ergocalciferol

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Chronic kidney disease: assessment and management (NG203)

NG203

NICE guideline

Updated Nov 2021

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Ergocalciferol

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

20555611000001100

dm+d ID

20555611000001100

VTM (Virtual Therapeutic Moiety)

775811005

VMP (Virtual Medicinal Product)

20555611000001100

BNF code

09060400

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

A11CC01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

1-2 days

Mechanism

For its activity, ergocalciferol is required to be transformed to its major acti…

Food interactions

None known

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Ergocalciferol is absorbed in the intestine and carried to the liver in chylomicrons.…

Half-life

1-2 days

Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.T577…

Protein binding

70-90%

Ergocalciferol is not found significantly distributed circulating in plasma.…

Volume of distribution

The amount of circulating ergocalciferol is very limited as this compound is rapidly stored in fat tissue such as adipose tissue, liver and muscle.…

Metabolism

Ergocalciferol is inactive and hence, the first step in the body is ruled by the conversion of this parent compound to 25-hydroxyvitamin D by…

Elimination

The active form of ergocalciferol, calcitrol, cannot be maintained for long periods in storage tissue mainly in periods of dietary or UVB deprivation.T577…

Clearance

31 ml/min

There are no formal reports regarding the clearance rate of ergocalciferol.…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Nutraceutical

Small molecule

About this compound

Ergocalciferol is an inactivated vitamin D analog.[A177526] It is synthesized by some plants in the presence of UVB light.T577 The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.T580

Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism.[A177637]

The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.[L6058]

Properties:

solid

Avg. mass: 396.65 Da

View FDA drug label

DrugBank indication

Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.[FDA label]

Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.
[L6082]

Rickets is a condition produced due to a deficiency in vitamin D, calcium or phosphorus. However, this condition can also be related to renal diseases.

It is characterized to present weak or soft bones.
[A177664]

Familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin D metabolism in the kidneys. The presence of this condition can derive in the presence of osteomalacia, bone softening and rickets.
[L6085]

Also known as(153)

(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol

(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

Activated ergosterol

Ercalciol

Ergocalciférol

Ergocalciferol

Ergocalciferolum

Dosage forms(38)

Capsule (Oral) — 600 UI

Capsule (Oral) — 20000 unit

Solution / drops (Oral)

Solution (Oral) — 1.18 mg

Capsule (Oral)

Capsule (Oral) — 1.25 mg/1

Capsule, liquid filled (Oral) — 1.25 mg/1

Liquid (Oral) — 0.2 mg/1mL

Molecular properties(19)

Drug interactions(145)

Known interactions with other medications. Always consult a healthcare professional.

Aluminum hydroxide

Unknown severity

DB06723

The serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.

Check this interaction

Danazol

Moderate

DB01406

Danazol may increase the hypercalcemic activities of Ergocalciferol.

Check this interaction

Sucralfate

Unknown severity

DB00364

The serum concentration of Sucralfate can be increased when it is combined with Ergocalciferol.

Check this interaction

Orlistat

Moderate

DB01083

Orlistat can cause a decrease in the absorption of Ergocalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Magnesium sulfate

Unknown severity

DB00653

The serum concentration of Magnesium sulfate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium salicylate

Unknown severity

DB01397

The serum concentration of Magnesium salicylate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magaldrate

Unknown severity

DB08938

The serum concentration of Magaldrate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium hydroxide

Unknown severity

DB09104

The serum concentration of Magnesium hydroxide can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium trisilicate

Unknown severity

DB09281

The serum concentration of Magnesium trisilicate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium chloride

Unknown severity

DB09407

The serum concentration of Magnesium chloride can be increased when it is combined with Ergocalciferol.

Check this interaction

Talc

Unknown severity

DB09511

The serum concentration of Talc can be increased when it is combined with Ergocalciferol.

Check this interaction

Hydrotalcite

Unknown severity

DB13322

The serum concentration of Hydrotalcite can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium aspartate

Unknown severity

DB13359

The serum concentration of Magnesium aspartate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium peroxide

Unknown severity

DB13486

The serum concentration of Magnesium peroxide can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium gluconate

Unknown severity

DB13749

The serum concentration of Magnesium gluconate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium orotate

Unknown severity

DB13786

The serum concentration of Magnesium orotate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium levulinate

Unknown severity

DB14514

The serum concentration of Magnesium levulinate can be increased when it is combined with Ergocalciferol.

Check this interaction

Magnesium lactate

Unknown severity

DB14515

The serum concentration of Magnesium lactate can be increased when it is combined with Ergocalciferol.

Check this interaction

Digoxin

Unknown severity

DB00390

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Digoxin.

Check this interaction

Acetyldigitoxin

Unknown severity

DB00511

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Acetyldigitoxin.

Check this interaction

Deslanoside

Unknown severity

DB01078

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Deslanoside.

Check this interaction

Ouabain

Unknown severity

DB01092

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Ouabain.

Check this interaction

Digitoxin

Unknown severity

DB01396

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Digitoxin.

Check this interaction

Oleandrin

Unknown severity

DB12843

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Oleandrin.

Check this interaction

Cymarin

Unknown severity

DB13240

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Cymarin.

Check this interaction

Proscillaridin

Unknown severity

DB13307

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Proscillaridin.

Check this interaction

Metildigoxin

Unknown severity

DB13401

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Metildigoxin.

Check this interaction

Lanatoside C

Unknown severity

DB13467

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Lanatoside C.

Check this interaction

Gitoformate

Unknown severity

DB13537

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Gitoformate.

Check this interaction

Acetyldigoxin

Unknown severity

DB13691

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Acetyldigoxin.

Check this interaction

Peruvoside

Unknown severity

DB13756

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Peruvoside.

Check this interaction

Mineral oil

Moderate

DB11057

Mineral oil can cause a decrease in the absorption of Ergocalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Methyclothiazide

Unknown severity

DB00232

The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Ergocalciferol.

Check this interaction

Bendroflumethiazide

Unknown severity

DB00436

The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Ergocalciferol.

Check this interaction

Benzthiazide

Unknown severity

DB00562

The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Ergocalciferol.

Check this interaction

Cyclothiazide

Unknown severity

DB00606

The risk or severity of hypercalcemia can be increased when Cyclothiazide is combined with Ergocalciferol.

Check this interaction

Hydroflumethiazide

Unknown severity

DB00774

The risk or severity of hypercalcemia can be increased when Hydroflumethiazide is combined with Ergocalciferol.

Check this interaction

Chlorothiazide

Unknown severity

DB00880

The risk or severity of hypercalcemia can be increased when Chlorothiazide is combined with Ergocalciferol.

Check this interaction

Hydrochlorothiazide

Unknown severity

DB00999

The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Ergocalciferol.

Check this interaction

Trichlormethiazide

Unknown severity

DB01021

The risk or severity of hypercalcemia can be increased when Trichlormethiazide is combined with Ergocalciferol.

Check this interaction

Polythiazide

Unknown severity

DB01324

The risk or severity of hypercalcemia can be increased when Polythiazide is combined with Ergocalciferol.

Check this interaction

Mebutizide

Unknown severity

DB13430

The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Ergocalciferol.

Check this interaction

Cyclopenthiazide

Unknown severity

DB13532

The risk or severity of hypercalcemia can be increased when Cyclopenthiazide is combined with Ergocalciferol.

Check this interaction

Buthiazide

Unknown severity

DB15861

The risk or severity of hypercalcemia can be increased when Buthiazide is combined with Ergocalciferol.

Check this interaction

Calcitriol

Unknown severity

DB00136

The risk or severity of adverse effects can be increased when Calcitriol is combined with Ergocalciferol.

Check this interaction

Calcifediol

Unknown severity

DB00146

The risk or severity of adverse effects can be increased when Calcifediol is combined with Ergocalciferol.

Check this interaction

Cholecalciferol

Unknown severity

DB00169

The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Cholecalciferol.

Check this interaction

Paricalcitol

Unknown severity

DB00910

The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Paricalcitol.

Check this interaction

Dihydrotachysterol

Unknown severity

DB01070

The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Dihydrotachysterol.

Check this interaction

Alfacalcidol

Unknown severity

DB01436

The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Alfacalcidol.

Check this interaction

Showing 50 of 145 interactions

Toxicity & overdose

The reported LD50 for orally administered ergocalciferol in the rat is of 10 mg/kg.MSDS Overdosage with this agent is reported to produce hypervitaminosis characterized by hypercalcemia, renal impairment, calcification of soft tissues, a decline in the rate of linear growth and increase in bone mineralization.
[L6094]

Once an overdose state is registered, immediate withdrawal of vitamin D is required along with a calcium diet, generous intake of fluids and symptomatic treatment. The administration of loop diuretics is an option to increase renal calcium excretion. On the other hand, dialysis and administration of citrates, sulfates, phosphates, corticosteroids, EDTA and mithramycin are recommended.
[L6094]

There haven't been long term studies analyzing the carcinogenic and mutagenic potential of ergocalciferol or its effects in fertility.

How it works

Mechanism of action

For its activity, ergocalciferol is required to be transformed to its major active circulating hydroxylated metabolite and transported to the target organs in order to bind to its target, the vitamin D receptor.T580

The activation of the vitamin D receptor is part of the vitamin D endocrine system and it is described by the production of a change in the transcription rates of the vitamin D receptor target genes.T580 The target genes in the DNA affected by the presence of ergocalciferol are called vitamin D response elements which are dependent on co-modulators.[A177637]

The vitamin D receptor is a transcription factor and member of the steroid hormone nuclear receptor family. It presents a DNA binding domain (VDRE) that, when activated, recruits coregulatory complexes to regulate the genomic activity.[A177637]

Additionally, ergocalciferol presents nongenomic effects such as the stimulation of intestinal calcium transport via transcaltachia.[A177637]

Pharmacodynamics

After the activation of the vitamin D receptor, some of the biological changes produced by ergocalciferol include mobilization and accretion of calcium and phosphorus in the bone, absorption of calcium and phosphorus in the intestine, and reabsorption of calcium and phosphorus in the kidney.T580

Some other effects known to be produced due to the presence of vitamin D are osteoblast formation, fetus development, induction of pancreatic function, induction of neural function, improvement of immune function, cellular growth and cellular differentiation.T580

When compared to its vitamin D counterpart [cholecalciferol], ergocalciferol has been shown to present a reduced induction of calcidiol and hence, it is less potent.[A177529]

Ergocalciferol supplementation in patients with end-stage renal disease has been shown to generate a significant benefit in lab parameters of bone and mineral metabolism as well as improvement in glycemic control, serum albumin levels and reduced levels of inflammatory markers.[A177526]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Ergocalciferol is absorbed in the intestine and carried to the liver in chylomicrons. Its intestinal absorption does not present limitations unless the presence of conditions related to fat malabsorption.T577 However, for absorption to take place, the presence of bile is required.
[L6088]

Half-life

Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.T577

Protein binding

Ergocalciferol is not found significantly distributed circulating in plasma. It is known to be found in its bound form to the vitamin D plasma protein.T592 The parent compound of ergocalciferol does not bind directly to plasma proteins, however, 70-90% of its metabolites such as cholecalciferol and calcitriol are found in the bound form.
[A177670]

Volume of distribution

The amount of circulating ergocalciferol is very limited as this compound is rapidly stored in fat tissue such as adipose tissue, liver and muscle. This is very obvious in reports that indicate that circulating ergocalciferol is significantly reduced in obese patients.T577

Metabolism

Ergocalciferol is inactive and hence, the first step in the body is ruled by the conversion of this parent compound to 25-hydroxyvitamin D by the action of CYP2R1 followed by the generation of the major circulating metabolite, 1,25-dihydroxyvitamin D or calcitrol.T577 The generation of this major metabolite is ruled by the activity of CYP27B1 which is a key 1-hydroxylase and CYP24A1 which is responsible for the 25-hydroxylation.
[A177637]

As part of the minor metabolism, ergocalciferol is transformed into 25-hydroxyvitamin D in the liver by the activity of D-25-hydroxylase and CYP2R1. As well, the formation of 24(R),25dihydroxyvitamin D is performed mainly in the kidneys by the action of 25-(OH)D-1-hydroxylase and 25-(OH)D-24-hydroxylase.T580

Additionally, there are reports indicating significant activity of 3-epimerase in the metabolism of ergocalciferol which modifies the hydroxy group in C3 from the alpha position to a beta. The epimers formed seemed to have a reduced affinity for the vitamin D plasma proteins and to the vitamin D receptor.
[A177637]

An alternative activation metabolic pathway has been reported and this process is characterized by the activity of CYP11A1 and its hydroxylation in the C-20.

This 20-hydroxylated vitamin D seems to have similar biological activity than calcitriol.
[A177637]

Route of elimination

The active form of ergocalciferol, calcitrol, cannot be maintained for long periods in storage tissue mainly in periods of dietary or UVB deprivation.T577 Therefore, ergocalciferol and its metabolites are excreted via the bile with a minor contribution of renal elimination. This major fecal elimination is explained due to the cubilin-megalin receptor system-mediated renal reuptake of vitamin D metabolites bound to vitamin D binding protein.
[L6091]

Clearance

There are no formal reports regarding the clearance rate of ergocalciferol. Due to the structural similarity, it is recommended to consult this parameter with [cholecalciferol]. On the other hand, the proposed renal clearance of calcitriol is of 31 ml/min.T140

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Vitamin D3 receptor

BE0000779

VDR

agonist

Specific functionbile acid nuclear receptor activity

Cellular location

Nucleus

General function & pharmacology

Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells .
PMID:10678179 PMID:15728261 PMID:16913708 PMID:28698609 PMID:37478846

Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR .
PMID:28698609
The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes .
PMID:28698609
Plays a central role in calcium homeostasis (By similarity). Also functions as a receptor for the secondary bile acid lithocholic acid (LCA) and its metabolites PMID:12016314 PMID:32354638

Voltage-dependent T-type calcium channel subunit alpha-1I

BE0004902

CACNA1I

inducer

Specific functionvoltage-gated calcium channel activity

Cellular location

Membrane

General function & pharmacology

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. This channel gives rise to T-type calcium currents. T-type calcium channels belong to the 'low-voltage activated (LVA)' group and are strongly blocked by nickel and mibefradil.

A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.

Gates in voltage ranges similar to, but higher than alpha 1G or alpha 1H

Metabolizing enzymes(6)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

RPERibulose-phosphate 3-epimerase

substrate

CYP11A1Cholesterol side-chain cleavage enzyme, mitochondrial

substrate

CYP24A11,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial

substrate

CYP27B125-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial

substrate

CYP27A1Sterol 26-hydroxylase, mitochondrial

substrate

CYP2R1Vitamin D 25-hydroxylase

substrate

Carriers(1)

Proteins that carry this drug through the body

Vitamin D-binding protein

BE0001141

binder

Specific functionactin binding

Cellular location

Secreted

General function & pharmacology

Involved in vitamin D transport and storage, scavenging of extracellular G-actin, enhancement of the chemotactic activity of C5 alpha for neutrophils in inflammation and macrophage activation

Scientific references(5)

Porter A., Gilmartin C., Srisakul U., Arruda J., Akkina S.

Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen.

American Journal Nephrol

201337(6):568-74. doi: 10.1159/000351185. Epub 2013 May 30

PMID: 23735861 DOI: 10.1159/000351185

Lee J.Y., So T.Y., Thackray J.

A review on vitamin d deficiency treatment in pediatric patients.

Journal Pediatrics Pharmacology Therapeutics

2013 Oct18(4):277-91. doi: 10.5863/1551-6776-18.4.277

PMID: 24719588 DOI: 10.5863/1551-6776-18.4.277

Gallagher J.C., Bikle D.D.

Vitamin D: Mechanisms of Action and Clinical Applications.

Endocrinol Metabolism Clinical North American

2017 Dec46(4):xvii-xviii. doi: 10.1016/j.ecl.2017.09.001. Epub 2017 Sep 28

PMID: 29080648 DOI: 10.1016/j.ecl.2017.09.001

Sahay M., Sahay R.K.

Refractory Rickets in Tropics.

Journal of Pediatric Endocrinology and Metabolism

201023(6). doi: 10.1515/jpem.2010.098

PMID: 20662333 DOI: 10.1515/jpem.2010.098

Hymoller L., Jensen S.K.

Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows.

Domest Anim Endocrinol

2017 Apr59:44-52. doi: 10.1016/j.domaniend.2016.11.002. Epub 2016 Nov 16

PMID: 27940098 DOI: 10.1016/j.domaniend.2016.11.002

ATC classification(1 code)

ATC A11CC01

Affected organisms(1)

Humans and other mammals

International brands(1)

Experimental properties(5)

External resources(3)

RxList PDRhealth Drugs.com

Protein Data Bank entries(1)

3czh

Commercial products(165)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Ergocalciferol

DB00153

CAS number

50-14-6

UNII (FDA)

VS041H42XC

InChI Key (molecular fingerprint)

MECHNRXZTMCUDQ-RKHKHRCZSA-N

Additional database identifiers

Drugs Product Database (DPD)

4924

Drugs Product Database (DPD)

703

ChEBI

28934

PubChem Compound

5280793

PubChem Substance

46505053

KEGG Compound

C05441

KEGG Drug

D00187

ChemSpider

4444351

BindingDB

50247883

PharmGKB

PA449484

PDB

D2V

Therapeutic Targets Database

DAP000291

Wikipedia

Ergocalciferol

ChEMBL

CHEMBL1536

ZINC

ZINC000004629876

RxCUI

4018

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12679

GenAtlas

VDR

GeneCards

VDR

GenBank Gene Database

J03258

GenBank Protein Database

340203

IUPHAR

605

Guide to Pharmacology

605

UniProtKB

P11473

UniProt Accession

VDR_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1405

GenAtlas

CACNG1

GeneCards

CACNG1

GenBank Gene Database

L07738

GenBank Protein Database

306473

UniProtKB

Q06432

UniProt Accession

CCG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1406

GeneCards

CACNG2

UniProtKB

Q9Y698

UniProt Accession

CCG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1407

GeneCards

CACNG3

UniProtKB

O60359

UniProt Accession

CCG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1408

GeneCards

CACNG4

UniProtKB

Q9UBN1

UniProt Accession

CCG4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1409

GeneCards

CACNG5

UniProtKB

Q9UF02

UniProt Accession

CCG5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13625

GeneCards

CACNG6

UniProtKB

Q9BXT2

UniProt Accession

CCG6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13626

GeneCards

CACNG7

UniProtKB

P62955

UniProt Accession

CCG7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13628

GeneCards

CACNG8

UniProtKB

Q8WXS5

UniProt Accession

CCG8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1399

GenAtlas

CACNA2D1

GeneCards

CACNA2D1

GenBank Gene Database

M76559

GenBank Protein Database

179762

UniProtKB

P54289

UniProt Accession

CA2D1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1400

GenAtlas

CACNA2D2

GeneCards

CACNA2D2

GenBank Gene Database

AJ251368

UniProtKB

Q9NY47

UniProt Accession

CA2D2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:15460

GeneCards

CACNA2D3

GenBank Gene Database

AJ272268

GenBank Protein Database

7105926

UniProtKB

Q8IZS8

UniProt Accession

CA2D3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20202

GeneCards

CACNA2D4

UniProtKB

Q7Z3S7

UniProt Accession

CA2D4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1393

GenAtlas

CACNA1F

GeneCards

CACNA1F

GenBank Gene Database

AJ006216

GenBank Protein Database

3183953

IUPHAR

531

Guide to Pharmacology

531

UniProtKB

O60840

UniProt Accession

CAC1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1397

GenAtlas

CACNA1S

GeneCards

CACNA1S

GenBank Gene Database

U30707

GenBank Protein Database

1698403

IUPHAR

528

Guide to Pharmacology

528

UniProtKB

Q13698

UniProt Accession

CAC1S_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1401

GenAtlas

CACNB1

GeneCards

CACNB1

GenBank Gene Database

M92303

GenBank Protein Database

179806

UniProtKB

Q02641

UniProt Accession

CACB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1402

GenAtlas

CACNB2

GeneCards

CACNB2

GenBank Gene Database

S60415

GenBank Protein Database

300417

UniProtKB

Q08289

UniProt Accession

CACB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1403

GenAtlas

CACNB3

GeneCards

CACNB3

GenBank Gene Database

X76555

GenBank Protein Database

435135

UniProtKB

P54284

UniProt Accession

CACB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1404

GenAtlas

CACNB4

GeneCards

CACNB4

GenBank Gene Database

U95020

GenBank Protein Database

2058727

UniProtKB

O00305

UniProt Accession

CACB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1389

GenAtlas

CACNA1B

GeneCards

CACNA1B

GenBank Gene Database

M94172

GenBank Protein Database

179758

IUPHAR

533

Guide to Pharmacology

533

UniProtKB

Q00975

UniProt Accession

CAC1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1388

GenAtlas

CACNA1A

GeneCards

CACNA1A

GenBank Gene Database

AF004884

GenBank Protein Database

2213913

IUPHAR

532

UniProtKB

O00555

UniProt Accession

CAC1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1392

GeneCards

CACNA1E

Guide to Pharmacology

534

UniProtKB

Q15878

UniProt Accession

CAC1E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1394

GenAtlas

CACNA1G

GenBank Gene Database

AF134986

GenBank Protein Database

6625659

IUPHAR

535

Guide to Pharmacology

535

UniProtKB

O43497

UniProt Accession

CAC1G_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1395

GenAtlas

CACNA1H

GeneCards

CACNA1H

GenBank Gene Database

AF051946

GenBank Protein Database

14670397

IUPHAR

536

Guide to Pharmacology

536

UniProtKB

O95180

UniProt Accession

CAC1H_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1396

GenAtlas

CACNA1I

GeneCards

CACNA1I

GenBank Gene Database

AF129133

GenBank Protein Database

5565888

IUPHAR

537

Guide to Pharmacology

537

UniProtKB

Q9P0X4

UniProt Accession

CAC1I_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10293

GeneCards

RPE

UniProtKB

Q96AT9

UniProt Accession

RPE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2590

GeneCards

CYP11A1

GenBank Gene Database

M14565

GenBank Protein Database

181376

Guide to Pharmacology

1358

UniProtKB

P05108

UniProt Accession

CP11A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2602

GenAtlas

CYP24A1

GeneCards

CYP24A1

GenBank Gene Database

L13286

GenBank Protein Database

306704

Guide to Pharmacology

1365

UniProtKB

Q07973

UniProt Accession

CP24A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2606

GenAtlas

CYP27B1

GeneCards

CYP27B1

GenBank Gene Database

AF027152

GenBank Protein Database

2612976

Guide to Pharmacology

1370

UniProtKB

O15528

UniProt Accession

CP27B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2605

GenAtlas

CYP27A1

GeneCards

CYP27A1

GenBank Gene Database

M62401

GenBank Protein Database

181292

Guide to Pharmacology

1369

UniProtKB

Q02318

UniProt Accession

CP27A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20580

GenAtlas

CYP2R1

GeneCards

CYP2R1

GenBank Gene Database

AY323817

GenBank Protein Database

33591222

UniProtKB

Q6VVX0

UniProt Accession

CP2R1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4187

GenAtlas

GeneCards

GenBank Gene Database

L10641

GenBank Protein Database

639896

UniProtKB

P02774

UniProt Accession

VTDB_HUMAN

International reference pricing

7 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.03/tablet

To $234.40/g

Longs vitamin d 400 unit tablet

$0.03/tablet

Vitamin d 400 unit softgel

$0.04/softgel capsule

Drisdol 8288 unit/ml Liquid

$0.48/ml

Drisdol 50000 unit capsule

$2.34/capsule

Doral 7.5 mg tablet

$3.37/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Ergocalciferol 400,000units/2ml solution for injection ampoules

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
9

Chemical identifiers

Ergocalciferol

Additional database identifiers

International reference pricing

DrugBank citations

Ergocalciferol 400,000units/2ml solution for injection ampoules

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science9

Chemical identifiers

Ergocalciferol

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
9